Written answers

Wednesday, 13 January 2016

Department of Health

Medicinal Products Availability

Photo of Olivia MitchellOlivia Mitchell (Dublin South, Fine Gael)
Link to this: Individually | In context | Oireachtas source

546. To ask the Minister for Health the status of funding for a cystic fibrosis drug called Orkambi. [46455/15]

Photo of Terence FlanaganTerence Flanagan (Dublin North East, Renua Ireland)
Link to this: Individually | In context | Oireachtas source

552. To ask the Minister for Health if funding will be provided to treat cystic fibrosis (details supplied); and if he will make a statement on the matter. [46506/15]

Photo of Tom FlemingTom Fleming (Kerry South, Independent)
Link to this: Individually | In context | Oireachtas source

556. To ask the Minister for Health if he will ensure that the cystic fibrosis drug Orkambi is made available at an early date as it is life-transforming to patients who have qualified for the drug and enables them lead a reasonable quality of life (details supplied); and if he will make a statement on the matter. [46520/15]

Photo of Arthur SpringArthur Spring (Kerry North-West Limerick, Labour)
Link to this: Individually | In context | Oireachtas source

561. To ask the Minister for Health if he has completed a cost-benefit analysis on the introduction of the drug Orkambi for patients with cystic fibrosis; and if he will make a statement on the matter. [46554/15]

Photo of Finian McGrathFinian McGrath (Dublin North Central, Independent)
Link to this: Individually | In context | Oireachtas source

583. To ask the Minister for Health to support a matter (details supplied) regarding cystic fibrosis; and if he will make a statement on the matter. [46693/15]

Photo of Billy KelleherBilly Kelleher (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

596. To ask the Minister for Health if the Health Service Executive will make Orkambi available to patients with DDF508 cystic fibrosis; and if he will make a statement on the matter. [46803/15]

Photo of Michael Healy-RaeMichael Healy-Rae (Kerry South, Independent)
Link to this: Individually | In context | Oireachtas source

613. To ask the Minister for Health his views on a matter (details supplied) from Cystic Fibrosis Ireland; and if he will make a statement on the matter. [46849/15]

Photo of Aengus Ó SnodaighAengus Ó Snodaigh (Dublin South Central, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

662. To ask the Minister for Health to take steps to make the drug Orkambi available to persons suffering from cystic fibrosis. [1236/16]

Photo of Michael Healy-RaeMichael Healy-Rae (Kerry South, Independent)
Link to this: Individually | In context | Oireachtas source

665. To ask the Minister for Health the status of Cystic Fibrosis patients (details supplied); and if he will make a statement on the matter. [1258/16]

Photo of Michael KittMichael Kitt (Galway East, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

693. To ask the Minister for Health the status of the provision of Orkambi to cystic fibrosis patients, where appropriate to do so; and if he will make a statement on the matter. [1431/16]

Photo of Kathleen LynchKathleen Lynch (Cork North Central, Labour)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 546, 552, 556, 561, 583, 596, 613, 662, 665 and 693 together.

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicinal products under the community drug schemes in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013. Prior to reimbursing any medicine, the HSE considers a range of statutory criteria, including clinical need, cost-effectiveness and the resources available to the HSE.

The decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds by the HSE on the advice of the National Centre for Pharmacoeconomics (NCPE). They are not political or ministerial decisions. The NCPE conducts the health technology assessment of pharmaceutical products for the HSE, and can make recommendations on reimbursement to assist the HSE in its decision-making process.

Orkambi™ is currently being considered by the HSE under the national medicines pricing and reimbursement assessment process. As the assessment process is ongoing, it is not possible to discuss potential outcomes or comment further at this time.

Comments

No comments

Log in or join to post a public comment.